Full Text View
Tabular View
No Study Results Posted
Related Studies
Monoclonal Antibody Therapy Plus Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
This study is ongoing, but not recruiting participants.
First Received: February 2, 2001   Last Updated: February 6, 2009   History of Changes
Sponsor: University of California, Davis
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00009750
  Purpose

RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining monoclonal antibody therapy and chemotherapy with peripheral stem cell transplantation may be an effective treatment for metastatic prostate cancer.

PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy plus chemotherapy followed by peripheral stem cell transplantation in treating patients who have metastatic prostate cancer that has not responded to hormone therapy.


Condition Intervention Phase
Prostate Cancer
 Biological: filgrastim
Biological: monoclonal antibody m170
Drug: cyclosporine
Drug: paclitaxel
Procedure: peripheral blood stem cell transplantation
Radiation: indium In 111 monoclonal antibody m170
Radiation: yttrium Y 90 monoclonal antibody m170
 Phase I

Study Type: Interventional
Study Design: Treatment, Open Label
Official Title: Combined Modality Radioimmunotherapy For Hormone Refractory Metastatic Prostate Cancer With Two Cycles Of Escalating Dose 90Y-DOTA-Peptide-m170 And Fixed, Low Dose Paclitaxel With Blood Stem Cell Support And Cyclosporin For HAMA Suppression

Resource links provided by NLM:

MedlinePlus related topics: Cancer Prostate Cancer
Drug Information available for: Paclitaxel Cyclosporine Indium in 111 oxyquinoline Cyclosporin Filgrastim Immunoglobulins Globulin, Immune
U.S. FDA Resources

Further study details as provided by National Cancer Institute (NCI):

Study Start Date: March 2001
Detailed Description:

OBJECTIVES:

  • Determine the maximum tolerated dose of yttrium Y90 monoclonal antibody m170 administered with paclitaxel and cyclosporine followed by autologous peripheral blood stem cell transplantation in patients with hormone-refractory metastatic prostate cancer.
  • Determine the preliminary efficacy of this regimen in these patients.

OUTLINE: This is an open-label, dose-escalation study of yttrium Y 90 monoclonal antibody m170 (Y90 MOAB m170). Patients are assigned to one of four cohorts.

After the first occurrence of hematologic dose-limiting toxicity in a patient, all subsequent patients receive filgrastim (G-CSF) subcutaneously (SC) beginning 4 days prior to undergoing apheresis and continuing until 6 million CD34+ cells/kg are collected. After 2 patients in a cohort group experience hematologic dose-limiting toxicity, subsequent patients undergo autologous peripheral blood stem cell (PBSC) transplantation.

  • Cohort I: Patients receive unlabeled monoclonal antibody (MOAB) m170 IV over 5 minutes followed by a tracer dose of indium In 111 monoclonal antibody m170 (In111 MOAB m170) IV over 5-10 minutes on day 0 and unlabeled MOAB m170 IV followed by Y90 MOAB m170 IV on day 7. Patients also receive oral cyclosporine every 12 hours on days -3 to 25. Patients may undergo autologous PBSC transplantation on day 21 and receive G-CSF SC daily beginning on day 21 and continuing until blood counts recover.
  • Cohort II: Patients receive treatment as in cohort I. Patients also receive paclitaxel IV over 3 hours on day 9.
  • Cohort III and IV: Patients receive treatment as in cohort I without In111 MOAB m170. Patients also receive paclitaxel as in cohort II.

Cohorts of 3 to 6 patients receive escalating doses of Y90 MOAB m170 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Patients are followed monthly for 3 months, every 3 months for 1 year, and then every 6 months for 1 year.

PROJECTED ACCRUAL: A total of 18-30 patients will be accrued for this study within 36 months.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed hormone-refractory metastatic prostate cancer
  • Hormonal ablation (surgical or chemical) at least 3 months prior to study
  • HAMA titer negative
  • Less than 25% bone marrow involvement by metastatic prostate cancer

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance status:

  • Karnofsky 70-100%

Life expectancy:

  • Not specified

Hematopoietic:

  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,00/mm^3
  • Hemoglobin at least 10.0 g/dL (without transfusion)
  • No chronic transfusion requirement

Hepatic:

  • Bilirubin no greater than 1.3 mg/dL
  • AST no greater than 1.5 times normal

Renal:

  • Creatinine less than 1.5 mg/dL

Cardiovascular:

  • LVEF at least 50% by MUGA
  • No disseminated intravascular coagulation

Pulmonary:

  • FEV1 at least 65% of predicted
  • FVC at least 65% of predicted
  • Corrected DLCO at least 60%

Other:

  • Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • No prior murine protein (e.g., ProstaScint)

Chemotherapy:

  • At least 4 weeks since prior standard dose chemotherapy

Endocrine therapy:

  • See Disease Characteristics

Radiotherapy:

  • At least 4 weeks since prior external beam radiotherapy
  • No prior radiotherapy to no more than 25% of total skeleton

Surgery:

  • See Disease Characteristics

Other:

  • No concurrent oral anticoagulants (low dose coumadin for central line thrombosis prophylaxis allowed)
  • No concurrent chronic transfusions
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00009750

Locations
United States, California
University of California Davis Cancer Center
Sacramento, California, United States, 95817
Sponsors and Collaborators
University of California, Davis
Investigators
Study Chair: Carol M. Richman, MD University of California, Davis
  More Information

Additional Information:
Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers: CDR0000068364, UCD-992126, NCI-V00-1639
Study First Received: February 2, 2001
Last Updated: February 6, 2009
ClinicalTrials.gov Identifier: NCT00009750     History of Changes
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
stage IV prostate cancer
recurrent prostate cancer

Additional relevant MeSH terms:
Anti-Infective Agents
Cyclosporine
Prostatic Diseases
Genital Neoplasms, Male
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Physiological Effects of Drugs
Urogenital Neoplasms
Cyclosporins
Antibodies, Monoclonal
Neoplasms by Site
Antifungal Agents
Therapeutic Uses
Dermatologic Agents
 Immunoglobulins
Mitosis Modulators
Enzyme Inhibitors
Antimitotic Agents
Genital Diseases, Male
Immunosuppressive Agents
Pharmacologic Actions
Antibodies
Neoplasms
Paclitaxel
Tubulin Modulators
Antirheumatic Agents
Antineoplastic Agents, Phytogenic
Prostatic Neoplasms

ClinicalTrials.gov processed this record on November 09, 2009



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services